Literature DB >> 86042

Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

W B Frijlink, O L Bijvoet, J te Velde, G Heynen.   

Abstract

18 patients with Paget's disease were treated orally with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). In most cases bone resorption became normal within a week of treatment, whereas the return to normal bone formation took 3-6 months; this difference produced a transient imbalance between resorption and formation. In biopsy specimens taken during treatment the numbers of osteoclasts and osteoblasts decreased towards normal and excess osteoid disappeared.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86042     DOI: 10.1016/s0140-6736(79)91318-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  63 in total

Review 1.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.

Authors:  S J Gallacher; S H Ralston; F J Dryburgh; F C Logue; B F Allam; B F Boyce; I T Boyle
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 3.  Treatment of osteoporosis: current and future.

Authors:  M D Stone; D J Hosking
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

4.  Hyperostosis induced by the bisphosphonate (2-PEBP) in the oophorectomized rat.

Authors:  C Movsowitz; S Epstein; M Fallon; F Ismail; S Thomas
Journal:  Calcif Tissue Int       Date:  1990-03       Impact factor: 4.333

5.  The bisphosphonates HEBP and AHPrBP but not AHBP inhibit mineral mobilization and lysosomal enzyme release from mouse calvarial bones in tissue culture.

Authors:  U Lerner; A Larsson
Journal:  Experientia       Date:  1984-09-15

6.  Paget's disease of bone: five regimens of pamidronate treatment.

Authors:  T Pepersack; R Karmali; C Gillet; D François; M Fuss
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

7.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

8.  Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.

Authors:  M E Stearns
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

Review 9.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

10.  Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.

Authors:  F Wingen; H Sterz; H Blum; H Möller; W Pittermann; B L Pool; H J Sinn; H Spring; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.